134 related articles for article (PubMed ID: 8610919)
1. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80.
Takeshita A; Shibata Y; Shinjo K; Yanagi M; Tobita T; Ohnishi K; Miyawaki S; Shudo K; Ohno R
Ann Intern Med; 1996 May; 124(10):893-6. PubMed ID: 8610919
[No Abstract] [Full Text] [Related]
2. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
[TBL] [Abstract][Full Text] [Related]
3. Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
Di Veroli A; Ramadan SM; Divona M; Cudillo L; Giannì L; Wieland S; Giannotti F; Mirabile M; Arcese W; Lo-Coco F
Br J Haematol; 2010 Oct; 151(1):99-101. PubMed ID: 20618325
[No Abstract] [Full Text] [Related]
4. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid.
Shinjo K; Takeshita A; Ohnishi K; Sakura T; Miyawaki S; Hiraoka A; Takeuchi M; Tomoyasu S; Wakita H; Ata K; Fukutani H; Ueda R; Ohno R;
Int J Hematol; 2000 Dec; 72(4):470-3. PubMed ID: 11197214
[TBL] [Abstract][Full Text] [Related]
5. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Ueda R; Ohno R; Harada M
Br J Haematol; 1997 Apr; 97(1):137-40. PubMed ID: 9136955
[TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
Takeuchi M
Gan To Kagaku Ryoho; 2006 Mar; 33(3):397-401. PubMed ID: 16531727
[TBL] [Abstract][Full Text] [Related]
7. [Retinoid therapy for autoimmune diseases].
Fukasawa H; Kagechika H; Shudo K
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Jun; 29(3):114-26. PubMed ID: 16819260
[TBL] [Abstract][Full Text] [Related]
8. [Long-term follow up of re-induction with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukemia previously treated with all-trans retinoic acid: results of 7 cases from a single institute].
Takeuchi M; Yoshida I; Takahashi K
Rinsho Ketsueki; 2003 Nov; 44(11):1069-73. PubMed ID: 14689869
[TBL] [Abstract][Full Text] [Related]
9. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
[TBL] [Abstract][Full Text] [Related]
10. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
11. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Inoue A; Kawakami C; Takitani K; Tamai H
Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
[No Abstract] [Full Text] [Related]
12. Promyelocytic leukemia retinoid signaling targets regulate apoptosis,tissue factor and thrombomodulin expression.
López-Pedrera C; Barbarroja N; Buendía P; Torres A; Dorado G; Velasco F
Haematologica; 2004 Mar; 89(3):286-95. PubMed ID: 15020266
[TBL] [Abstract][Full Text] [Related]
13. [Management of relapsed acute promyelocytic leukemia].
Emi N
Nihon Rinsho; 2012 Apr; 70 Suppl 2():420-4. PubMed ID: 23133993
[No Abstract] [Full Text] [Related]
14. Tamibarotene-induced low-grade reversible intravascular coagulation in a patient with acute promyelocytic leukemia.
Ohata K; Yamazaki H; Asakura H; Shimadoi S; Nakao S
Thromb Res; 2012 Feb; 129(2):213-4. PubMed ID: 21820159
[No Abstract] [Full Text] [Related]
15. Tamibarotene.
Miwako I; Kagechika H
Drugs Today (Barc); 2007 Aug; 43(8):563-8. PubMed ID: 17925887
[TBL] [Abstract][Full Text] [Related]
16. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm.
Shudo K; Kagechika H; Yamazaki N; Igarashi M; Tateda C
Biol Pharm Bull; 2004 Nov; 27(11):1887-9. PubMed ID: 15516744
[TBL] [Abstract][Full Text] [Related]
17. Tamibarotene: a candidate retinoid drug for Alzheimer's disease.
Fukasawa H; Nakagomi M; Yamagata N; Katsuki H; Kawahara K; Kitaoka K; Miki T; Shudo K
Biol Pharm Bull; 2012; 35(8):1206-12. PubMed ID: 22863914
[TBL] [Abstract][Full Text] [Related]
18. [Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 3. Treatment for acute promyelocytic leukemia].
Kiyoi H
Nihon Naika Gakkai Zasshi; 2013 Jul; 102(7):1705-11. PubMed ID: 23947232
[No Abstract] [Full Text] [Related]
19. The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis.
Sato A; Watanabe K; Kaneko K; Murakami Y; Ishido M; Miyasaka N; Nanki T
Mod Rheumatol; 2010 Jun; 20(3):244-51. PubMed ID: 20039185
[TBL] [Abstract][Full Text] [Related]
20. Tamibarotene: AM 80, retinobenzoic acid, Tamibaro.
Drugs R D; 2004; 5(6):359-62. PubMed ID: 15563242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
